symbol__ Stock Quote Price and Forecast

Fundamental Variance — Alpha Tau Medical Ltd.

• Net Income: −34.26% YoY; −89.02% QoQ

• EPS: −16.52% YoY; −80.45% QoQ

• Total Revenue: not disclosed in the available data set

• Sector classification: Health Technology / Medical Specialties (small-cap)

• Operating stage: clinical-stage oncology therapeutics; headquarters Jerusalem, Israel

• Indications under trial: skin cancer, oral cavity cancer, breast cancer, pancreatic cancer

The +1.12% session delta coinciding with a −80.45% sequential EPS contraction defines the current price-fundamental variance profile. No revenue line is reported.

Large-Cap Reference Points (Headline-Level)

Additional inputs from the source cluster, limited to title and snippet extraction:

• GOOGL (Alphabet Inc.): active quote feed maintained on Yahoo Finance; no extractable price level from the current snippet.

• MSFT: per Stocktwits commentary, Dan Ives frames MSFT as the most oversold large-cap, drawing structural parallels to negative sentiment around GOOGL twelve months prior. No quantitative figures are available in the snippet.

• Astar: headline-level coverage only from Kabul University domain; no price, date, or forecast metrics extractable.

These inputs are insufficient for cross-asset correlation modeling in the current evidence set.

Technical Levels and Probability Assessment

DRTS operative levels:

• Resistance: upper boundary of the 52-week range (exact print not contained in the evidence set)

• Support: 200-day simple moving average (exact value not contained in the evidence set)

• Session delta: +1.12%

• Sequential EPS variance: −80.45% QoQ

Probability read: with price at the 52-week range extreme and quarterly earnings momentum at −80.45%, mean reversion probability increases on a multi-quarter horizon. Near-term continuation probability remains non-trivial given the +1.12% session delta and SMA-clearing positioning. The confidence interval around any directional call remains wide absent revenue disclosure, forward guidance, and sector beta inputs.

Monitoring protocol: a daily close below the 200-day SMA, paired with continued EPS deterioration, raises mean reversion probability materially. A close above the 52-week range upper boundary on above-average volume would invalidate the mean reversion thesis on the short-term horizon. Pivot signal: SMA hold-or-fail at the next session.